RLS Stock Overview
RLS Global AB (publ), a medical technology company, develops and sells products for minimally invasive treatment in Sweden.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
RLS Global AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.45 |
| 52 Week High | SEK 3.49 |
| 52 Week Low | SEK 0.21 |
| Beta | 0.57 |
| 11 Month Change | -26.16% |
| 3 Month Change | -35.36% |
| 1 Year Change | -84.18% |
| 33 Year Change | -93.07% |
| 5 Year Change | -93.59% |
| Change since IPO | -70.27% |
Recent News & Updates
Shareholder Returns
| RLS | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -0.2% | -1.5% | -1.4% |
| 1Y | -84.2% | 38.6% | 20.7% |
Return vs Industry: RLS underperformed the Swedish Pharmaceuticals industry which returned 28.5% over the past year.
Return vs Market: RLS underperformed the Swedish Market which returned 5.8% over the past year.
Price Volatility
| RLS volatility | |
|---|---|
| RLS Average Weekly Movement | 18.5% |
| Pharmaceuticals Industry Average Movement | 11.0% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 10.9% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: RLS's share price has been volatile over the past 3 months.
Volatility Over Time: RLS's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 9 | Roland Frosing | rls.global |
RLS Global AB (publ), a medical technology company, develops and sells products for minimally invasive treatment in Sweden. Its products include ChloraSolv that is used for the treatment of chronic diabetic foot and leg ulcers for diabetic patients; and CariSolv, a gel used for removing caries. RLS Global AB (publ), was founded in 1996 and is based in Mölndal, Sweden.
RLS Global AB (publ) Fundamentals Summary
| RLS fundamental statistics | |
|---|---|
| Market cap | SEK 35.62m |
| Earnings (TTM) | -SEK 28.81m |
| Revenue (TTM) | SEK 1.08m |
33.1x
P/S Ratio-1.2x
P/E RatioIs RLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RLS income statement (TTM) | |
|---|---|
| Revenue | SEK 1.08m |
| Cost of Revenue | SEK 5.10m |
| Gross Profit | -SEK 4.02m |
| Other Expenses | SEK 24.78m |
| Earnings | -SEK 28.81m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Nov 23, 2023
| Earnings per share (EPS) | -0.36 |
| Gross Margin | -374.07% |
| Net Profit Margin | -2,677.32% |
| Debt/Equity Ratio | 0% |
How did RLS perform over the long term?
See historical performance and comparison